Garden Grove, California 92845

  • Schizophrenia

Purpose:

This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.


Criteria:

Inclusion Criteria: - Willing and able to provide written informed consent. - Male or female patients 18 to 65 years of age (inclusive). - Clinical diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorder (DSM-5) for at least 1 year. - Symptomatically stable within the past two months. Exclusion Criteria: - Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. - Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs. - Pregnant or nursing (lactating) women. - A positive test for drugs of abuse.


NCT ID:

NCT04712734


Primary Contact:

Vanda Pharmaceuticals Inc.
Phone: 202-734-3400
Email: VYV683@vandapharma.com


Backup Contact:

N/A


Location Contact:

Garden Grove, California 92845
United States

Vanda Pharmaceuticals Inc.
Phone: 202-734-3400

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: July 26, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.